Abstract

Many pathogenic viruses rely on class I fusion proteins to fuse their viral membrane with the host cell membrane. To drive the fusion process, class I fusion proteins undergo an irreversible conformational change from a metastable prefusion state to an energetically more stable postfusion state. Mounting evidence underscores that antibodies targeting the prefusion conformation are the most potent, making it a compelling vaccine candidate. Here, we establish a computational design protocol that stabilizes the prefusion state while destabilizing the postfusion conformation. With this protocol, we stabilize the fusion proteins of the RSV, hMPV, and SARS-CoV-2 viruses, testing fewer than a handful of designs. The solved structures of these designed proteins from all three viruses evidence the atomic accuracy of our approach. Furthermore, the humoral response of the redesigned RSV F protein compares to that of the recently approved vaccine in a mouse model. While the parallel design of two conformations allows the identification of energetically sub-optimal positions for one conformation, our protocol also reveals diverse molecular strategies for stabilization. Given the clinical significance of viruses using class I fusion proteins, our algorithm can substantially contribute to vaccine development by reducing the time and resources needed to optimize these immunogens.

The authors present a generalisable computational approach to stabilize class I fusion proteins in the prefusion state. The method was used to stabilize the fusion proteins of RSV, hMPV, and SARS-CoV-2 viruses, with the designs structurally validated and RSV F protein assessed in a neutralization assay.

Details

Title
A general computational design strategy for stabilizing viral class I fusion proteins
Author
Gonzalez, Karen J. 1   VIAFID ORCID Logo  ; Huang, Jiachen 2 ; Criado, Miria F. 3 ; Banerjee, Avik 2 ; Tompkins, Stephen M. 2   VIAFID ORCID Logo  ; Mousa, Jarrod J. 4   VIAFID ORCID Logo  ; Strauch, Eva-Maria 5   VIAFID ORCID Logo 

 University of Georgia, Institute of Bioinformatics, Franklin College of Arts and Sciences, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X) 
 University of Georgia, Department of Infectious Diseases, College of Veterinary Medicine, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X); University of Georgia, Center for Vaccines and Immunology, College of Veterinary Medicine, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X) 
 University of Georgia, Center for Vaccines and Immunology, College of Veterinary Medicine, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X); Auburn University, Department of Pathobiology, College of Veterinary Medicine, Auburn, USA (GRID:grid.252546.2) (ISNI:0000 0001 2297 8753) 
 University of Georgia, Department of Infectious Diseases, College of Veterinary Medicine, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X); University of Georgia, Center for Vaccines and Immunology, College of Veterinary Medicine, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X); University of Georgia, Department of Biochemistry and Molecular Biology, Franklin College of Arts and Sciences, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X) 
 University of Georgia, Institute of Bioinformatics, Franklin College of Arts and Sciences, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X); University of Georgia, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X); Washington University, Department of Medicine, School of Medicine, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002) 
Pages
1335
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2925767198
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.